PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No. 8859

Lucile MIQUEROL et al.

Atty. Docket No. 029440.00005

Serial No.: 10/825,687

Examiner: NOBLE, Marcia Stephens

Filed: April 16, 2004

Art Unit: 1632

For: MOUSE CARDIAC CONDUCTION SYSTEM MODEL

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: September 28, 2007

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required. \boxtimes This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. П I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1). П I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

		c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.	
	3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.		
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).	
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).	
OPTIC	DNAL P	ARAGRAPH 4:	
	4.	Copy/Copies of the U.S. Patent reference(s) is/are not enclosed.	
	4. preser	The relevance of the non-English language references(s) is discussed in the at specification.	
	4. The reference(s) was/were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.		
	4. referer	A concise explanation of the relevance of the non-English language nce(s) appears in the Appendix attached hereto.	
	secred patent	The Examiner's attention is directed to co-pending U.S. Patent Application, filed, which is directed to related technical subject matter. The cation of this U.S. Patent Application is not to be construed as a waiver of as to that application now or upon issuance of the present application as a . The Examiner is respectfully requested to consider the cited application and cited therein during examination of the present application.	
	4. This application is one of a series of related applications, identified in the attached Appendix, which are directed to related technical subject matter. The identification of those U.S. Patent Applications is not to be construed as a waive secrecy as to those applications nor or upon issuance of the present application patent. The Examiner is respectfully requested to consider the cited application		

	and the art cited therein during the examination.			
		The reference(s) was/were cited by or submitted to the Office in parent dication No, filed, which is relied upon for an earlier filing date ler 35 U.S.C. § 120. Thus, copies of these references are not attached. 37 CFR 98(d).		
	4. are att	An English-language Abstract(s) of the non-English language reference(s) attached hereto.		
	4.	Other.		
In the event that any fees are due with respect to this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 01-2300, referencing Atty. Docket No				
		Respectfully submitted,		
		Patricia D. Granados Registration No. 33 683		

Customer No. 004372
ARENT FOX LLP
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339

Washington, D.C. 20036-5339 Tel: (202) 857-6000 Fax: (202) 638-4810

PDG/knc